Sign in
Taking people in United StatesPhase 3

Long-term dazukibart treatment for dermatomyositis and polymyositis in adults who took part before

Follows adults with dermatomyositis or polymyositis who earlier tried dazukibart, testing its long-term safety.

Key facts

Who runs it
Pfizer
Where
Beckley, Frisco, Glendale, and Houston, United StatesSee the 4 sitesAlso in 14 other countries, 29 sites
Registry title
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Status
Recruiting
Phase
Phase 3
People taking part
211 people, planned
Started
22 Jan 2025
Expected to end
29 Jul 2031
Type of study
Interventional
Treatments tested
  • Dazukibart
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dermatomyositis or polymyositis who took part in an earlier dazukibart study. Some will get dazukibart, others will only have safety check-up visits.

Age
18 years and older
Sex
All sexes
Disease stage
Active idiopathic inflammatory myopathy (dermatomyositis or polymyositis), as described in the summary.
Earlier treatment
People must have completed an earlier qualifying dazukibart study through Week 52.

Main reasons for not taking part

  • Medical or mental health problems, or lab results, that make taking part riskier, including suicidal thoughts or behaviour in the past year or now
  • Another study drug or vaccine other than dazukibart within 30 days or 5 half-lives before the start, whichever is longer
  • Current use of medicines not allowed in the study
  • Active infection of any kind (bacterial, viral, fungal or other)
  • An ongoing side effect or safety problem from the earlier study that has not gone away

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants that completed a qualifying study through Week 52

Who cannot take part

  • Previous administration with an investigational product (drug or vaccine) other than dazukibart in a qualifying study within 30 days (or as determined by the local requirement) or 5 half-lives preceding baseline in this study (whichever is longer)
  • Current use of any prohibited concomitant medication(s)
  • Active bacterial, viral, fungal, mycobacterial or other infections
  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
  • Ongoing adverse event in a qualifying study or the participant has met safety monitoring criteria in a qualifying study that have not resolved
  • Investigator site staff or sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members

Where in United States

Also in 14 other countries, 29 sites

  • Rheumatology & Pulmonary ClinicBeckley, United StatesNo longer taking part
  • Arthritis & Rheumatology Research Institute, PLLCFrisco, United StatesNot yet recruiting
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - GlendaleGlendale, United StatesTaking people
  • Nerve & Muscle Center of TexasHouston, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]).

Read full original descriptionShow less

Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM.

DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hips, thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathies may find it difficult to climb stairs, get up from a seated position, or lift items above their head. People with DM can also have a skin rash.

These disorders negatively impact the quality of life and functioning of patients. In addition to the above, these disorders can affect how the lungs and heart work.

This study is seeking participants who took part in a DM and PM study with dazukibart before. Some participants will receive study medicine, and some participants will not receive study medicine and only complete safety follow-up.

The study medicine will be given as an intravenous (IV) infusion (directly into the veins). This takes about 1 hour, every 4 weeks, from Day 1 to Week 48 (about 12 months) of the study. This will be followed by a safety follow-up period that lasts about 4 months after the last infusion. Participants who receive study medicine will have about 18 study visits at the site over about 16 months.

There will also be participants enrolled in this study who will not receive study medicine. Such participants will only take part in safety follow-up visits as they do not want to or are not eligible to receive dazukibart. These participants will not receive study medicine and will have up to 4 study visits at the site every 4 weeks to complete safety follow-up.

The group in the trial

  • DazukibartTreatment being tested

    Participants will receive dazukibart via intravenous infusion every 4 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)
Plain-language title
Long-term dazukibart treatment for dermatomyositis and polymyositis in adults who took part beforeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
25 August 2026